Athanase Innovation (ATIN) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Net revenue for Q4 2024 was SEK 29.4m, up from SEK 15.8m in Q4 2023; full-year revenue reached SEK 115.3m, up from SEK 19.3m year-over-year.
Value change from securities was SEK 21.0m in Q4 (SEK 2.6m in Q4 2023) and SEK 53.5m for the year (SEK 21.3m in 2023).
Operating result (EBIT) improved to SEK -0.01m in Q4 (SEK -27.3m in Q4 2023) and SEK -23.7m for the year (SEK -79.2m in 2023).
CEO transition: Peter Laveson stepped down, Daniel Nyhrén Edeen appointed as interim CEO.
Voluntary redemption program returned SEK 91.8m to shareholders; 3.8m shares redeemed at SEK 24 per share.
Financial highlights
Ivisys, the wholly owned subsidiary, contributed all group revenue, completing several installations and selling 10 PalletAl units in 2024 (4 in 2023).
Group cash flow for Q4 was SEK -115.4m (SEK -80.4m in Q4 2023); year-to-date cash flow was SEK -146.1m (SEK -179.3m in 2023).
Cash and cash equivalents at year-end were SEK 310.6m (SEK 457.2m at end 2023).
Earnings per share for Q4 was SEK -0.02 (SEK -0.48 in Q4 2023); for the year, SEK -0.83 (SEK -1.89 in 2023).
Equity ratio at year-end was 87.8% (92.8% at end 2023).
Outlook and guidance
Ivisys order book at year-end was SEK 26.6m; additional orders received after the period.
The board is evaluating a potential tax-free distribution of subsidiaries via Lex Asea and will await tax authority feedback before proceeding with delisting plans.
No dividend proposed for 2024.
Latest events from Athanase Innovation
- Revenue and EBIT fell significantly as Ivisys project deliveries slowed and legal costs rose.ATIN
Q4 202520 Feb 2026 - Sales and earnings fell, but portfolio companies delivered strong growth amid legal challenges.ATIN
Q3 20254 Nov 2025 - Net sales grew but operating losses widened in Q2 2025, driven by negative securities value changes.ATIN
Q2 202511 Jul 2025 - Q3 sales soared but losses deepened; board proposes share redemption and delisting.ATIN
Q3 202413 Jun 2025 - Q2 saw higher revenue, strong value gains, and improved EBIT, led by Ivisys and Zalaris.ATIN
Q2 202413 Jun 2025 - Sharp drop in sales and earnings; Ivisys spin-off and strong Zalaris, Pace growth.ATIN
Q1 20256 Jun 2025